UCB SA (UCBJY)
OTCMKTS
· Delayed Price · Currency is USD
89.67
+2.72 (3.13%)
Nov 20, 2024, 4:00 PM EST
UCB SA Revenue
UCB SA had revenue of 2.79B EUR in the half year ending June 30, 2024, a decrease of -2.24%. This brings the company's revenue in the last twelve months to 5.45B, up 3.32% year-over-year. In the year 2023, UCB SA had annual revenue of 5.18B, down -4.87%.
Revenue (ttm)
5.45B EUR
Revenue Growth
+3.32%
P/S Ratio
n/a
Revenue / Employee
600.46K EUR
Employees
9,083
Market Cap
34.66B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5.18B | -265.00M | -4.87% |
| Dec 31, 2022 | 5.45B | -330.00M | -5.71% |
| Dec 31, 2021 | 5.78B | 430.00M | 8.04% |
| Dec 31, 2020 | 5.35B | 434.00M | 8.83% |
| Dec 31, 2019 | 4.91B | 281.00M | 6.07% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.69B |
| Ryman Healthcare Limited | 411.39M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.53M |
| Medexus Pharmaceuticals Inc. | 104.76M |
UCB SA News
- 1 day ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
- 1 day ago - FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease - Benzinga
- 1 day ago - UCB gets FDA approval for Bimzelx for hidradenitis suppurativa - Seeking Alpha
- 2 days ago - Biogen, UCB release phase 3 data on lupus candidate dapirolizumab - Seeking Alpha
- 9 days ago - United Community Banks: Too Rich For My Blood - Seeking Alpha
- 5 weeks ago - Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy - Seeking Alpha
- 2 months ago - UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024 - Benzinga
- 2 months ago - UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024 - Benzinga